三分之一常规剂量光敏剂维替泊芬联合光动力疗法治疗急性中心性浆液性脉络膜视网膜病变多中心临床效果观察

发布时间：2018-03-18 16:40

本文选题：视网膜疾病　切入点：光敏感药　出处：《中国全科医学》2014年21期 　论文类型：期刊论文

【摘要】：目的观察1/3常规剂量光敏剂维替泊芬联合光动力疗法(PDT)治疗急性中心性浆液性脉络膜视网膜病变(CSC)的有效性和安全性。方法选取2011年10月—2012年10月沈阳医学院沈洲医院、中国医科大学第一临床学院、沈阳市第四人民医院确诊的急性CSC患者90例(90眼),均接受1/3常规剂量维替泊芬静脉推注(2 mg/m2),静脉推注开始5 min后接受波长689 nm激光照射83 s。治疗后1周和1、3、6个月随访,比较治疗前后最佳矫正视力(BCVA)、视网膜下积液面积、黄斑中心凹视网膜厚度(CFT),观察不良反应。结果治疗后较治疗前BCVA提高,视网膜下积液面积减少,CFT变薄(P0.05)。BCVA、视网膜下积液面积、CFT治疗前到治疗后1个月内明显好转,治疗后1个月到6个月基本稳定,无不良反应发生。结论 1/3常规剂量光敏剂维替泊芬联合PDT治疗急性CSC能停止或减少脉络膜血管渗漏,促进视网膜解剖复位,改善症状,提高和稳定视力,无明显不良反应。
[Abstract]:Objective to observe the efficacy and safety of 1/3 routine dose Guang Min combined with photodynamic therapy in the treatment of acute central serous chorioretinopathy. Methods from October 2011 to October 2012, Shenzhou Hospital of Shenyang Medical College was selected. The first Clinical College of China Medical University, 90 patients with acute CSC diagnosed in 4th people's Hospital of Shenyang were treated with 1/3 routine dose of vitipofen intravenously injected with 2 mg / m ~ 2g 路m ~ (2), followed up for 6 months by 689nm laser irradiation at the wavelength of 83s after 5 min of intravenous injection. The best corrected visual acuity (BCV), the area of subretinal effusion and the retinal thickness of macular fovea were compared before and after treatment, and the adverse reactions were observed. The area of subretinal effusion decreased and CFT thinned (P0.05N. BCVA). The area of subretinal effusion was significantly improved from 1 month to 1 month after treatment, and was basically stable from 1 month to 6 months after treatment. Conclusion 1/3 routine dose of Guang Min combined with PDT can stop or reduce choroidal vascular leakage, promote retinal anatomical reattachment, improve symptoms, improve and stabilize visual acuity, and have no obvious adverse reactions.
【作者单位】：沈阳医学院沈洲医院眼科;北京大学医学部基础医学院;中国医科大学第一临床学院眼科;沈阳市第四人民医院眼科;
【分类号】：R774.1

【相似文献】